Effectiveness of a multicomponent pharmacist intervention at hospital discharge for drug-related problems: A cluster randomised cross-over trial.
cluster randomised cross-over trial
communication
community pharmacist
drug-related problem
hospital discharge
hospital pharmacist
medication reconciliation
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
21
01
2020
revised:
07
04
2020
accepted:
18
04
2020
pubmed:
10
5
2020
medline:
30
6
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
The aim of this study was to assess whether a pharmacist intervention associating medication reconciliation at discharge with a link to the community pharmacist reduces drug-related problems (DRP) in adult patients during the 7 days after hospital discharge in 22 university or general hospitals in France. We conducted a cluster randomised cross-over superiority trial with hospital units as the cluster unit. The primary outcome was a composite of any kind of DRP (prescription/dispensation, patient error or gap due to no medication available) during the 7 days after discharge, assessed by phone with the patient and community pharmacist. Among secondary outcomes, we studied self-reported unplanned hospitalisations at day 35 after discharge and severe iatrogenic problems. A total of 1092 patients were enrolled in 48 units (538 in the experimental periods and 554 in the control periods). Three patients refused to have their data analysed and were excluded from the analyses. As compared with usual care, the pharmacist intervention led to a lower proportion of patients with at least one DRP (44.0% vs 50.6%; odds ratio [OR] 0.77, 95% confidence interval [CI] 0.61-0.98) and severe iatrogenic problems (5.2% vs 8.7%; OR 0.57, 95% CI 0.35-0.93) but no significant difference in unplanned hospitalisations at day 35 (5.8% vs 4.5%; OR 1.46, 95% CI 0.91-2.35). Medication reconciliation associated with communication between the hospital and community pharmacist may decrease patient exposure to DRP and severe iatrogenic problems but not unplanned hospitalisation. However, this intervention could be recommended in health policies to improve drug management.
Identifiants
pubmed: 32383801
doi: 10.1111/bcp.14349
pmc: PMC7688527
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2441-2454Subventions
Organisme : French Ministry of Health
ID : PREPS 12-010-0054
Informations de copyright
© 2020 The British Pharmacological Society.
Références
Int J Clin Pharm. 2012 Feb;34(1):113-9
pubmed: 22207271
Br J Clin Pharmacol. 2020 Dec;86(12):2441-2454
pubmed: 32383801
J Clin Pharm Ther. 2016 Apr;41(2):128-44
pubmed: 26913812
Am J Health Syst Pharm. 2006 Dec 15;63(24):2500-3
pubmed: 17158698
JAMA. 2007 Feb 28;297(8):831-41
pubmed: 17327525
Biometrics. 2004 Sep;60(3):807-11
pubmed: 15339305
Am J Health Syst Pharm. 2015 Jun 1;72(11 Suppl 1):S36-42
pubmed: 25991594
Ann Pharmacother. 2004 May;38(5):859-67
pubmed: 15054145
Health Aff (Millwood). 2015 May;34(5):836-43
pubmed: 25941286
Jt Comm J Qual Patient Saf. 2015 Oct;41(10):457-61
pubmed: 26404074
Arch Intern Med. 2009 Nov 23;169(21):2003-10
pubmed: 19933963
Pharm World Sci. 2009 Dec;31(6):630-7
pubmed: 19649720
Cochrane Database Syst Rev. 2016 Feb 20;2:CD008986
pubmed: 26895968
Pharm World Sci. 2006 Aug;28(4):181-8
pubmed: 17066245
BMJ. 2016 Aug 16;354:i4291
pubmed: 27530617
Biometrics. 2004 Dec;60(4):919-25
pubmed: 15606412
J Hosp Med. 2007 Sep;2(5):314-23
pubmed: 17935242
Res Social Adm Pharm. 2017 Jul - Aug;13(4):661-685
pubmed: 27665364
Hosp Pharm. 2016 Jun;51(6):468-73
pubmed: 27354748
Eur J Clin Pharmacol. 2017 Nov;73(11):1355-1377
pubmed: 28744584
Hosp Pharm. 2015 Jun;50(6):505-13
pubmed: 26405342
Ann Pharmacother. 2010 Nov;44(11):1747-54
pubmed: 20923946
Stat Med. 2008 Nov 29;27(27):5578-85
pubmed: 18646266
BMC Clin Pharmacol. 2012 Apr 03;12:9
pubmed: 22471836
Trials. 2014 Jun 30;15:260
pubmed: 24981605
Int J Clin Pharm. 2016 Oct;38(5):1149-56
pubmed: 27432017
J Clin Epidemiol. 2005 Mar;58(3):246-51
pubmed: 15718113
Am J Health Syst Pharm. 2002 Nov 15;59(22):2221-5
pubmed: 12455306
N Engl J Med. 2009 Apr 2;360(14):1418-28
pubmed: 19339721
PLoS Med. 2007 Feb;4(2):e61
pubmed: 17311468
J Hosp Med. 2016 Jan;11(1):39-44
pubmed: 26434752
Int J Clin Pharm. 2012 Dec;34(6):797-802
pubmed: 23054139